摘要
目的:观察替雷利珠单抗注射液联合甲磺酸仑伐替尼胶囊治疗老年中晚期原发性肝癌患者的效果。方法:选取2021年5月至2023年2月该院收治的96例老年中晚期原发性肝癌患者进行前瞻性研究,按照随机数字表法分为研究组与对照组各48例。对照组采用甲磺酸仑伐替尼胶囊治疗,研究组在对照组基础上联合替雷利珠单抗注射液治疗,比较两组客观缓解率、血清肿瘤标志物[糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)、癌胚抗原(CEA)]水平、T细胞亚群指标水平和不良反应发生率。结果:治疗后,两组血清CA19-9、AFP、CEA水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于治疗前,且研究组高于对照组,两组CD8^(+)水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);两组客观缓解率、不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗注射液联合甲磺酸仑伐替尼胶囊治疗老年中晚期原发性肝癌患者可降低血清肿瘤标志物水平,改善T细胞亚群指标水平,效果优于单纯甲磺酸仑伐替尼胶囊治疗。
Objective:To observe effects of Tislelizumab injection combined with Lenvatinib mesylate capsules in treatment of elderly patients with advanced primary liver cancer.Methods:A prospective study was conducted on 96 elderly patients with advanced primary liver cancer admitted to this hospital from May 2021 to February 2023.According to the random number table method,they were divided into study group and control group,48 cases in each group.The control group was treated with Lenvatinib mesylate capsules,while the study group was treated with Tislelizumab injection on the basis of the control group.The objective remission rate,the serum tumor markers [carbohydrate antigen 19-9(CA19-9),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)] levels,the T cell subset levels,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the levels of serum CA19-9,AFP and CEA in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+) and CD4^(+)/CD8^(+) in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the level of CD8^(+) in the two groups was lower than that before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the objective remission rate and the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tislelizumab injection combined with Lenvatinib mesylate capsule in the treatment of the elderly patients with advanced primary liver cancer can reduce the levels of serum tumor markers and improve the levels of T cell subsets.Moreover,it is superior to single Lenvatinib mesylate capsules treatment.
作者
邱丽倩
王起飞
QIU Liqian;WANG Qifei(1^(st)Department of Oncology of Hua County People’s Hospital,Anyang 456400 Henan,China)
出处
《中国民康医学》
2024年第6期45-47,共3页
Medical Journal of Chinese People’s Health